Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...
Sutro Biopharma, located in South San Francisco...
We are a clinical stage, publicly traded specialty pharmaceutical company, focused...
We are a clinical stage, publicly traded specia...
Mustang Bio, Inc. (âMustangâ), a Fortress Biotech Company, is a clinical-stage...
Mustang Bio, Inc. (âMustangâ), a Fortress B...
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
Join the National Investor Network and get the latest information with your interests in mind.